| abstract |
The invention relates to novel interfuranylene-prostacyclin derivatives of the general formula (I) ##STR1## wherein R 1 stands for hydrogen or a straight or branched chain C 1-6 alkyl group, an inorganic cation or for the protonated form of a base containing an amino group; n R 2 stands for hydrogen, a C 1-4 alkanoyl or benzoyl group, a monosubstituted benzoyl, trialkylsilyl or an alkoxyalkyl group; n R 3 stands for a straight or branched chain C 1-6 alkyl group, a phenyl group optionally substituted by halogen or by a C 1-4 alkyl group, a heteroaryl group optionally substituted by halogen or by a C 1-4 alkyl group or a cycloalkyl group; n A stands for an ethylene or for a cis- or trans-vinylene or --C.tbd.C-- group; n B means a chemical bond, a --CHR 5 --, --CHR 5 --CH 2 -- or a --CH 2 --O-- group: and n R 5 means hydrogen or a C 1-4 alkyl group. n The compounds of the formula (I) can be used therapeutically as platelet aggregation inhibiting, anti-thrombotic, hypotensive and anti-antherosclerotic agents; they are much more stable than the natural prostacyclin derivatives. |